Relapses of Immune Thrombocytopenia after the Second and Booster Doses of BNT162b2 Vaccine.

IF 1.7 4区 医学 Q3 HEMATOLOGY Acta Haematologica Pub Date : 2023-01-01 DOI:10.1159/000527431
Maja Ratajczak-Enselme, Guy-Clébert Mutoni, Jules Demeules, Laurence Favet, Kuntheavy Ing Lorenzini
{"title":"Relapses of Immune Thrombocytopenia after the Second and Booster Doses of BNT162b2 Vaccine.","authors":"Maja Ratajczak-Enselme,&nbsp;Guy-Clébert Mutoni,&nbsp;Jules Demeules,&nbsp;Laurence Favet,&nbsp;Kuntheavy Ing Lorenzini","doi":"10.1159/000527431","DOIUrl":null,"url":null,"abstract":"<p><p>We present here a 65-year-old male patient known for immune thrombocytopenic purpura (ITP) and fluctuating platelet count who experienced a severe exacerbation of thrombocytopenia following BNT162b2 COVID-19 vaccination. One month after the second dose, he presented petechiae and asthenia with isolated thrombocytopenia (platelet count: 3 × 109/L). He recovered after a 4-day course of intravenous corticosteroid treatment and intravenous immunoglobulin therapy. Eight months later, his platelet count was within the normal range, and he received a booster dose of vaccine after premedication with prednisone. Eight days later, his platelet count dropped to 29 × 109/L, but he remained asymptomatic. He received a rescue treatment with prednisone followed by rituximab over 4 weeks, allowing progressive improvement. Our case suggests a strong association between COVID-19 vaccination and the exacerbation of ITP.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":"146 1","pages":"52-57"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000527431","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

We present here a 65-year-old male patient known for immune thrombocytopenic purpura (ITP) and fluctuating platelet count who experienced a severe exacerbation of thrombocytopenia following BNT162b2 COVID-19 vaccination. One month after the second dose, he presented petechiae and asthenia with isolated thrombocytopenia (platelet count: 3 × 109/L). He recovered after a 4-day course of intravenous corticosteroid treatment and intravenous immunoglobulin therapy. Eight months later, his platelet count was within the normal range, and he received a booster dose of vaccine after premedication with prednisone. Eight days later, his platelet count dropped to 29 × 109/L, but he remained asymptomatic. He received a rescue treatment with prednisone followed by rituximab over 4 weeks, allowing progressive improvement. Our case suggests a strong association between COVID-19 vaccination and the exacerbation of ITP.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
第二剂和加强剂BNT162b2疫苗后免疫性血小板减少症复发。
我们在这里报告了一名65岁的男性患者,已知为免疫性血小板减少性紫癜(ITP)和血小板计数波动,他在接种BNT162b2 COVID-19疫苗后经历了严重的血小板减少症恶化。第二次给药1个月后,患者出现瘀点、虚弱,伴孤立性血小板减少(血小板计数3 × 109/L)。经4天的静脉皮质类固醇治疗和静脉免疫球蛋白治疗后恢复。8个月后,他的血小板计数在正常范围内,他在预用药强的松后接受了加强剂量的疫苗接种。8天后,患者血小板计数降至29 × 109/L,但仍无症状。他接受了强的松和利妥昔单抗的抢救治疗,持续了4周,病情逐渐好转。本病例提示COVID-19疫苗接种与ITP恶化之间存在密切关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Haematologica
Acta Haematologica 医学-血液学
CiteScore
4.90
自引率
0.00%
发文量
61
审稿时长
6-12 weeks
期刊介绍: ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.
期刊最新文献
Shorter duration of Blinatumomab administration to 14 days has same efficacy and safety profile in treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A retrospective single-center study. Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm. Efficacy of haploidentical allogeneic hematopoietic cell transplantation following two courses of venetoclax and azacytidine therapy in patients over 55 years old with acute myelogenous leukemia. Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis. Sudden Blast Crisis in a chronic myeloid leukemia patient in Treatment Free Remission: A case report and literature review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1